Target Price | $93.50 |
Price | $63.48 |
Potential | 47.29% |
Number of Estimates | 26 |
26 Analysts have issued a price target Lam Research 2026 . The average Lam Research target price is $93.50. This is 47.29% higher than the current stock price. The highest price target is $125.00 96.91% , the lowest is $70.00 10.27% . | |
A rating was issued by 33 analysts: 23 Analysts recommend Lam Research to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lam Research stock has an average upside potential 2026 of 47.29% . Most analysts recommend the Lam Research stock at Purchase. |
26 Analysts have issued a sales forecast Lam Research 2025 . The average Lam Research sales estimate is $17.7b . This is 9.45% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $18.0b 10.86% , the lowest is $17.2b 6.09% .
This results in the following potential growth metrics:
2024 | $14.9b | 14.47% |
---|---|---|
2025 | $17.7b | 19.02% |
2026 | $18.2b | 2.44% |
2027 | $20.2b | 11.05% |
2028 | $23.2b | 15.15% |
2029 | $24.2b | 4.08% |
15 Analysts have issued an Lam Research EBITDA forecast 2025. The average Lam Research EBITDA estimate is $5.9b . This is 13.49% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.0b 16.21% , the lowest is $5.6b 7.11% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 16.82% |
---|---|---|
2025 | $5.9b | 25.61% |
2026 | $5.9b | 0.85% |
2027 | $6.9b | 15.94% |
2028 | $8.2b | 19.44% |
2029 | $8.7b | 6.19% |
2024 | 31.43% | 2.75% |
---|---|---|
2025 | 33.17% | 5.53% |
2026 | 32.66% | 1.54% |
2027 | 34.10% | 4.41% |
2028 | 35.37% | 3.72% |
2029 | 36.08% | 2.01% |
19 Lam Research Analysts have issued a net profit forecast 2025. The average Lam Research net profit estimate is $4.8b . This is 14.06% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.9b 17.02% , the lowest is $4.7b 10.64% .
This results in the following potential growth metrics and future Net Margins:
2024 | $3.7b | 12.65% |
---|---|---|
2025 | $4.8b | 29.40% |
2026 | $4.9b | 1.91% |
2027 | $5.9b | 19.33% |
2028 | $6.5b | 11.32% |
2029 | $7.9b | 21.06% |
2024 | 25.00% | 2.12% |
---|---|---|
2025 | 27.18% | 8.72% |
2026 | 27.04% | 0.52% |
2027 | 29.05% | 7.43% |
2028 | 28.09% | 3.30% |
2029 | 32.67% | 16.30% |
19 Analysts have issued a Lam Research forecast for earnings per share. The average Lam Research EPS is $3.75 . This is 13.98% higher than earnings per share in the financial year 2024. The highest EPS forecast is $3.85 17.02% , the lowest is $3.64 10.64% .
This results in the following potential growth metrics and future valuations:
2024 | $2.90 | 12.65% |
---|---|---|
2025 | $3.75 | 29.31% |
2026 | $3.82 | 1.87% |
2027 | $4.56 | 19.37% |
2028 | $5.08 | 11.40% |
2029 | $6.15 | 21.06% |
Current | 19.29 | 42.67% |
---|---|---|
2025 | 16.92 | 12.29% |
2026 | 16.60 | 1.89% |
2027 | 13.91 | 16.20% |
2028 | 12.50 | 10.14% |
2029 | 10.32 | 17.44% |
Based on analysts' sales estimates for 2025, the Lam Research stock is valued at an EV/Sales of 4.55 and an P/S ratio of 4.59 .
This results in the following potential growth metrics and future valuations:
Current | 4.99 | 36.99% |
---|---|---|
2025 | 4.55 | 8.73% |
2026 | 4.45 | 2.38% |
2027 | 4.00 | 9.95% |
2028 | 3.48 | 13.16% |
2029 | 3.34 | 3.93% |
Current | 5.03 | 36.91% |
---|---|---|
2025 | 4.59 | 8.64% |
2026 | 4.48 | 2.38% |
2027 | 4.04 | 9.95% |
2028 | 3.51 | 13.16% |
2029 | 3.37 | 3.92% |
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 22 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Apr 16 2025 |
Stifel |
Buy
➜
Buy
|
Unchanged | Apr 15 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Apr 14 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Apr 11 2025 |
Jefferies |
Buy
➜
Buy
|
Unchanged | Mar 28 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Feb 20 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Apr 22 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Apr 16 2025 |
Unchanged
Stifel:
Buy
➜
Buy
|
Apr 15 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Apr 14 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Apr 11 2025 |
Unchanged
Jefferies:
Buy
➜
Buy
|
Mar 28 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Feb 20 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.